Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer (TA439)

Technology Appraisal Guidance No. 439

Source: National Institute for Health and Care Excellence

This guidance replaces NICE technology appraisal guidance on cetuximab for the first-line treatment of metastatic colorectal cancer (TA176).

This guidance partially updates the terminated NICE technology appraisal on panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (TA240).

1. Guidance

1.1  Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with:

  • 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) or
  • 5-fluorouracil, folinic acid and irinotecan (FOLFIRI)

1.2 Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:

  • FOLFOX or
  • FOLFIRI

1.3 The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.


A copy of the full document and background is available on the Internet at http://guidance.nice.org.uk/TA439

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:nice@nice.org.uk

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
Issue Date: March 2017
Review Date: March 2020


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases